COMPARATIVE ALBENDAZOLE SULPHOXIDE PHARMACOKINETICS AFTER SINGLE ORAL ADMINISTRATION OF THREE DIFFERENT FORMULATIONS IN DOGS.

DIB, A.,; PALMA S.,; SUÁREZ,; G. FARÍAS,; C., CABRERA, A,; ALLEMANDI D.,; MORENO, L.,; SÁNCHEZ BRUNI, S,.; LANUSSE, C

Tandil

Congreso; XL Reunión anual de la Sociedad Argentina de Farmacología Experimental; 2008

Sociedad Argentina de Farmacología Experimental

New therapeutics alternatives using Benzimidazole compound are being studied to improve posology and antiparasite efficacy. The aim of this work was to compare plasma pharmacokinetics (PK) profiles of three different oral Albendazole (ABZ)-based formulations in dogs. Nine animals were randomly divided into three groups and two phases (incomplete block design). Phase I (n=9): Group I (formulation A): received 25 mg/kg of ABZ conventionally formulated. Group II (formulation B) received 25mg/kg of a modified ABZ formulation (poloxamer solid dispersion)). Group III (Formulation C), received Albendazole Sulfoxide (ABZSO) (equimolar dose). After 21 days of wash-out period the experiment was repeatead as Phase II. Blood samples were taken over 24h and subsequently analyzed by HPLC. ABZSO and ABZSO2 were the analytes recovered in plasma. Significant (P<0.001) AUC values (+500%) and Cmax (+487%) for ABZSO, were obtained for the formulation C when statiscally compared with A and B. However, no statistical differences on PK parameters were found between A and B formulations. In conclusion formulation C, showed the best trend as potential antiparasite activity.